Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
about
Umbilical cord blood transplantation for the treatment of hematologic malignanciesSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyOutcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.Demethylating Agents in the Treatment of CancerHematopoietic stem cell transplantation for MDS.Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasHematopoietic stem-cell transplantation for advanced systemic mastocytosis.Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and MarrowCurrent status of allogeneic hematopoietic cell transplantation for MDS.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsHematopoietic stem cell transplantation for chronic lymphocytic leukemia.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Insights and hopes in umbilical cord blood stem cell transplantationsFactors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota.Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndromeCD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased RelapseMonosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS.Managing myelodysplastic symptoms in elderly patients.Transplantation for myelodysplastic syndromes 2013.Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome.Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Update on the pharmacotherapy for myelodysplastic syndromes.The myelodysplastic syndromes: the era of understanding.Stopping higher-risk myelodysplastic syndrome in its tracks.Predictive factors for rapid neutrophil and platelet engraftment after allogenic peripheral blood stem cell transplantation in patients with acute leukemia.Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation.Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.Myelodysplastic syndromes--many new drugs, little therapeutic progress.A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients.
P2860
Q26820829-807208AB-6AA1-47FA-807E-A84193ADD1F9Q27010653-C6950EF1-D8A4-4D7B-85B7-6C98D38B3A0DQ30252975-D15B5FF4-2F5E-413A-8AF3-80FE30577174Q33678040-E31FB078-8223-407E-8110-5FA3584BA4AAQ33767314-50282574-4312-4B14-8A0B-DB5DF539B465Q33850163-22FC1266-CB09-4B94-8681-2336BBBA2795Q34664111-8978DE24-97FA-49BF-9326-351E78E590BEQ35000581-26F552D5-DB26-4C67-918F-A6FCD49C0507Q35714782-54BFF5D6-D45C-49E1-A268-A75C2C2A57D6Q36063049-5096BA8C-DC11-4FED-95AB-94A10E577EC7Q36380188-CC805CD6-2FFB-4A79-A74E-04C0D0643CD0Q36416452-AF803F0B-B664-4630-B37C-7B22343D7DC2Q36431041-1A4B534C-D4A5-4BA8-AC9E-BEEE3BDC3A37Q36432837-5D5A9130-D5BC-4D4A-9615-E8ACA2B3314AQ36499044-E3356DD9-E441-456B-BDFE-0D4CBEA7FEBDQ36544315-29A67180-0C1F-49C1-8770-7781396836B4Q36608689-1BB50E07-F693-4CD7-A0FA-BCFBC4995946Q36683757-66701EFA-A575-42AB-A50B-5287318B293DQ36890784-A226AE6A-64F8-4C49-A5E3-2791A9799C2CQ37448906-1BE5EAE7-3E34-409E-A0E5-33B1A7E1404FQ37600407-D4AFF6A6-80BE-40DB-A1AB-38F18E7AA808Q37656412-86B83173-9427-444B-AB24-9B47ABB23257Q37707098-6A04DA51-FCC5-49D8-9673-975CDFAFC300Q37739020-E1246D14-9A6C-41DF-944E-3E271207BB34Q37964938-3946EECA-FB24-45F7-AEE4-000A3923E6D4Q38235662-8DB42A35-4E4C-4A26-AE7F-FF186E06878EQ38245878-F4F154B6-CD9A-4C99-B5A0-83B9B26A29BCQ38248180-65517476-4706-4A21-B696-1E59DA341C63Q38448204-246917CC-2CEB-488F-A1A6-395D22695464Q38737783-0F01DC0B-D358-45E5-8D3B-E84ACD09EF4FQ39157279-429FA21C-59EC-4F25-8D6B-EF4362C3C58CQ39527812-90E573D7-F251-4548-998D-68A89AE9B9DBQ39632454-DF2274DE-0ED0-4E27-B557-8D13D52240A3Q40370775-21B11A09-D381-4243-94AA-FE71F4E8257AQ40766061-9B931557-7D7F-4AFA-BB4F-A4B76E6577CDQ40829969-729C3536-AF4A-4B89-9C23-7EC7879C4D2FQ42186622-0C182C51-3597-44EF-BA2A-492445616FAEQ43085409-FC794A67-6E6E-4994-8BE3-044112AB3DAAQ43451303-16DC1D62-6076-41E6-9A10-FF4EC242C30BQ44066797-270E109A-9D93-4A5C-BA58-336E062B37B6
P2860
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Allogeneic stem cell transplan ...... pretransplant disease burden.
@ast
Allogeneic stem cell transplan ...... pretransplant disease burden.
@en
Allogeneic stem cell transplan ...... pretransplant disease burden.
@nl
type
label
Allogeneic stem cell transplan ...... pretransplant disease burden.
@ast
Allogeneic stem cell transplan ...... pretransplant disease burden.
@en
Allogeneic stem cell transplan ...... pretransplant disease burden.
@nl
prefLabel
Allogeneic stem cell transplan ...... pretransplant disease burden.
@ast
Allogeneic stem cell transplan ...... pretransplant disease burden.
@en
Allogeneic stem cell transplan ...... pretransplant disease burden.
@nl
P2093
P1476
Allogeneic stem cell transplan ...... pretransplant disease burden.
@en
P2093
Adina Cioc
Daniel Weisdorf
Erica D Warlick
Michelle Dolan
Todd Defor
P356
10.1016/J.BBMT.2008.10.012
P577
2009-01-01T00:00:00Z